As the world transitions from the acute phase of the COVID-19 pandemic, a novel concern
has arisen—interstitial lung disease (ILD) as a consequence of SARS-CoV-2 infection. This …

This review proposes a model of Long-COVID where the constellation of symptoms are in
fact genuinely experienced persistent physical symptoms that are usually functional in …

In late 2019, COVID-19 emerged. Within a few months, local outbreaks rapidly developed
into a viral infectious global pandemic. With nearly 1 billion people experiencing this novel …

While ground-glass opacity, consolidation, and fibrosis in the lungs are some of the
hallmarks of acute SAR-CoV-2 infection, it remains unclear whether these pulmonary …

Lung cancer is the leading cause of cancer mortality in the world. It greatly affects the
patients' quality of life, and is thus a challenge for the daily practice in respiratory medicine …

Objectives To investigate changes in chest CT between 3 and 12 months and associations
with disease severity in patients hospitalized for COVID-19 during the first wave in 2020 …

Pirfenidone and Nintedanib are specific drugs used against idiopathic pulmonary fibrosis
(IPF) that showed efficacy in non-IPF fibrosing interstitial lung diseases (ILD). Both drugs …

Current studies agree on the impact of sleep and circadian rest–activity rhythm alterations in
acute respiratory distress syndrome (ARDS) survivors. However, research on the duration of …

The literature reports that there was a significant difference in the medical impact of the
coronavirus disease (COVID-19) pandemic between European and East Asian countries; …

Rationale and Objectives It remains difficult to predict longitudinal outcomes in long-COVID,
even with chest CT and functional MRI. 129 Xe MRI reflects airway dysfunction, measured …